Emmaus Life Sciences

Emmaus Life Sciences, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of treatments for rare and orphan diseases. The company's primary product is Endari, an oral pharmaceutical-grade L-glutamine powder designed to reduce acute complications of sickle cell disease in both adult and pediatric patients aged five years and older. In addition to Endari, Emmaus is developing other therapeutic products, including those targeting diverticulosis and utilizing cell sheet technology for corneal diseases. Founded in 2000 and headquartered in Torrance, California, the company was previously known as Emmaus Holdings, Inc. before rebranding in 2011. Emmaus Life Sciences aims to address significant unmet medical needs through its innovative therapies.